HOME OUR COMPANY TECHNOLOGY & INNOVATION R&D PORTFOLIO INVESTORS PARTNERSHIPS NEWS & EVENTS CAREERS CONTACT NANOBODIES® – CREATING BETTER MEDICINES LEARN MORE 1 2 3 4 Ablynx is dedicated to creating new medicines which will make a real difference to society Our Products The Company has more than 45 proprietary and partnered product candidates in development Learn more. Events & Presentations Ablynx participates and presents at IR and scientific conferences Learn more. Investors Ablynx is listed on Euronext Brussels under the ticker symbol ABLX. Learn more. Latest News ABLYNX ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE PHASE III HERCULES STUDY OF CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP 02 October 2017 ABLYNX ANNOUNCES WARRANT EXERCISE 14 September 2017 ABLYNX TO PRESENT AT UPCOMING INVESTOR CONFERENCES IN LONDON 07 September 2017 ALL NEWS >> Stock Quote ABLX € 15.50 3.18 +25.81% Updated at 15:35 CET Download Corporate presentation Fact sheet Shareholders structure MORE >> Video TITAN study - Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura ABLYNX ON YOUTUBE >> Contact Us Ablynx nv Technologiepark 21 9052 Ghent/Zwijnaarde Belgium info@ablynx.com Tel: +32 (0)9 262 00 00 Fax: +32 (0)9 262 00 01 Annual Report Annual report 2016 Stay in touch Click the button below to subscribe to the Ablynx news service SUBSCRIBE 2015 - 2017 © Ablynx Disclaimer Sitemap Our Company Technology & innovation R&D portfolio Investors Partnerships News & events Careers Contact